HAMPTON, N.J., June 16, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced additions to the Board of Directors and senior management team:
  • Keith L. Brownlie was elected to the Company's Board of Directors at Celldex's 2017 Annual Meeting of Stockholders held yesterday. Mr. Brownlie was employed by the accounting firm Ernst & Young LLP from 1974 to 2010, where he served as audit partner for numerous public companies and was the Life Sciences Industry Leader for the New York metropolitan area.
  • Sam Martin has been promoted to Senior Vice President and Chief Financial Officer, effective July 1, 2017. Mr. Martin joined Celldex in April 2009 and currently serves as Vice President, Finance. As previously announced, Mr. Martin will assume the responsibilities of Avery "Chip" Catlin, who is retiring on June 30, 2017.
  • Sarah Cavanaugh has been promoted to Senior Vice President, Corporate Affairs and Administration. Ms. Cavanaugh joined Celldex in August 2012 as Vice President of Investor Relations and Corporate Communications. She will continue fulfilling those responsibilities and will assume leadership for human resources, employee relations, organizational development and internal communications.

"Keith brings an exceptional background in finance and accounting within the life sciences industry," said Larry Ellberger, Chairman of the Board of Directors at Celldex Therapeutics. "We believe he will be a valuable addition to the Board of Directors as a whole, and in particular, to the audit committee, which he will chair."

"Sam's expertise in corporate finance and established leadership at Celldex over the last eight years has been critical to the organization. His knowledge of our business has ensured a smooth transition with Chip's pending retirement," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. "For five years, Sarah has led our investor relations group and provided communications counsel throughout the company. During that time, she has played an increasing role in organizational development and will be instrumental in ensuring that we further strengthen the culture of Celldex and develop our people. I look forward to continuing to work with them both in their new capacities."

If you liked this article you might like

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) Is Strong On High Volume Today